Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial
In: Journal of Clinical Oncology, Jg. 36 (2018-05-20), S. 572-572
Online
unknown
Zugriff:
572Background: The ADAPT HER2+/HR+ phase II trial (NCT01745965) compared for the first time 12 wks. neoadjuvant T-DM1 (+/- endocrine therapy (ET)) with trastuzumab (T)+ET; pCR (ypT0/is ypN0) was > ...
Titel: |
Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial
|
---|---|
Autor/in / Beteiligte Person: | Liedtke, Cornelia ; Sanne de Haas ; Kleine-Tebbe, Anke ; Malter, Wolfram ; Braun, Michael ; Aktas, Bahriye ; Kates, Ronald E. ; Forstbauer, Helmut ; Deurloo, Regula ; Christgen, Matthias ; Harbeck, Nadia ; Tio, J. ; Nitz, Ulrike ; Wuerstlein, Rachel ; Kreipe, Hans ; Gluz, Oleg ; Augustin, Doris ; Kümmel, Sherko ; Schumacher, Claudia ; Potenberg, Jochem |
Link: | |
Zeitschrift: | Journal of Clinical Oncology, Jg. 36 (2018-05-20), S. 572-572 |
Veröffentlichung: | American Society of Clinical Oncology (ASCO), 2018 |
Medientyp: | unknown |
ISSN: | 1527-7755 (print) ; 0732-183X (print) |
DOI: | 10.1200/jco.2018.36.15_suppl.572 |
Schlagwort: |
|
Sonstiges: |
|